- Center believes the CyberKnife System is the #1 tool for
delivery of advanced radiosurgery treatments
- Selected the latest generation CyberKnife S7™ System to
increase the number of indications they can treat throughout the
body, and the patients they can help
SUNNYVALE, Calif., Jan. 26,
2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:
ARAY) announced today that the European Radiosurgery Center Munich
has selected a second CyberKnife® System, the
latest generation CyberKnife S7™ System, to enable their team to
treat the high volume of patients they see in their practice who
would benefit from the extremely precise radiation treatments it
delivers. The Center was an early adopter of CyberKnife
radiosurgery and continues to pioneer new ways to use the system in
the non-invasive treatment of certain neurological conditions and
tumors.
With almost 18 years of experience using the CyberKnife platform
and more than 10,000 patients treated, the European Radiosurgery
Center Munich team is one of the foremost experts in the delivery
of radiosurgery treatments – a technique in which very focused,
high doses of radiation are delivered to a specific area of the
body over a short period of time. This out-patient treatment
process necessitates an extremely high degree of precision and
accuracy. Patients eligible for radiosurgery treatments benefit
from the shorter overall course of care, typically 1 to 2 sessions
in Munich, compared to
conventional radiation therapy which often requires 30-40 sessions,
and experience less disruption to their daily lives.
"Our team in Munich is thrilled
to enhance our CyberKnife capabilities with the newest generation
of the system. I believe that CyberKnife is the #1 technology in
the field for delivering radiosurgery, our preferred approach when
appropriate for our patients," said Prof. Dr. Alexander Muacevic,
Director European Radiosurgery Center Munich. "The volume of
patients we see who would benefit from treatment far exceeds our
ability to provide care with our current system so we made the
decision to focus on select tumor types. The installation of an
additional system will enable our team to treat a wider range of
cases, particularly those in the body, extending the benefits – of
CyberKnife and radiosurgery – to more patients."
The CyberKnife S7 System was designed to provide clinicians with
the speed required for workflow efficiency while maintaining the
precision and accuracy required for radiosurgery treatments. The
Accuray exclusive Synchrony® technology enables the
system to continually track and automatically correct the beam for
patient or tumor movement in real-time throughout the entire
treatment session.
Suzanne Winter, president and CEO
of Accuray said, "We are grateful for the long-term trust of Prof.
Dr. Muacevic and his team in our company and products. I believe
the CyberKnife S7 System's unique capabilities align with their
goals – and the healthcare community's – to deliver better, faster
care that enables patients to get back to living their lives more
quickly.
"The European Radiosurgery Center Munich team, through their
commitment to continually revolutionizing radiosurgery, has
established a protocol for delivering treatments using the
CyberKnife System that has enriched the lives of thousands of
patients over almost two decades. Their achievements demonstrate
what is possible when an expert medical care team is partnered with
the right technology."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn,
Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, including new product
innovations and releases; the company's ability to develop new
products or improve existing products to meet customers' needs; the
company's ability to anticipate or keep pace with changes in the
marketplace; and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's Quarterly Report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
November 3, 2022, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/european-radiosurgery-center-munich-invests-in-second-accuray-cyberknife-system-to-support-the-demand-for-high-precision-radiosurgery-treatments-301731318.html
SOURCE Accuray Incorporated